Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of medical economics"
DOI: 10.1080/13696998.2023.2165365
Abstract: Background: Galcanezumab (GMB) improved quality of life and reduced disability of patients with episodic (EM) and chronic migraine (CM) in Phase 3 trials.Aim: To estimate indirect cost savings associated with GMB treatment in patients with… read more here.
Keywords: annual indirect; analysis; work school; work ... See more keywords